▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #633 by analyst upside · 2026-09-29
QNCX
Quince Therapeutics, Inc.
Healthcare · Market Cap $29M · P/E 0x
ANALYST PRICE TARGET
+160.1%
implied upside to consensus target
Current Price $29.0
Consensus Target $75.43
Bull Target $98.0
Bear Target $65.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
1
Sell
0
52-Week Low $15.1
52-Week High $910.0
YTD Return -95.2%
FUNDAMENTALS
Market Cap $29M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-210.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.1
52-Week High $910.0
Current Price $29.0
Bear Target $65.0
Bull Target $98.0
● Now $29.0 ● Target $75.43
TRADING DATA
Avg Volume 31K
YTD Return -95.2%
Analyst Count 7
Consensus Buy
Upside to Target +160.1%
Last Updated 2026-09-29

ANALYST SUMMARY

Quince Therapeutics, Inc. (QNCX) is currently trading at $29.0 with a Wall Street consensus price target of $75.43, implying potential upside of 160.1% over the next 12 months. 7 analysts currently cover QNCX, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $98.0, while the most cautious has a target of $65.0.

QNCX operates in the Healthcare sector with a market capitalisation of $29M. The stock is down 95.2% year-to-date and is currently trading near the lower end of its 52-week range of $15.1 – $910.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ATNM +205.1%
Actinium Pharmaceuticals, Inc.
$37M · P/E 3.4x · Buy
BTMD +112.4%
biote Corp.
$42M · P/E 8.8x · Buy
ELOX +155.0%
Eloxx Pharmaceuticals, Inc.
$52M · P/E 4.3x · Buy
FBIO +130.4%
Fortress Biotech, Inc.
$72M · P/E 0.8x · Buy
NEPH +55.1%
Nephros, Inc.
$44M · P/E 26.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for QNCX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Rodman & Renshaw ● Initiated
Buy 2026-09-24 29% win rate (7 calls)
Citizens ↑ Upgrade
Market Perform → Market Outperform 2026-09-22 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-08-18 40% win rate (10 calls)
Oppenheimer ● Initiated
Outperform → Outperform 2026-07-29 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2026-06-24 29% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-06-23 40% win rate (10 calls)
Citizens ↓ Downgrade
Market Outperform → Market Perform 2026-01-30 Building track record
D. Boral Capital ↓ Downgrade
Buy → Hold 2026-01-30 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
16/30
Consensus clarity
7/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →